Entrada Therapeutics (TRDA) News Today → A Wave of Creative Destruction Set to Strike June 30 (From Banyan Hill Publishing) (Ad) Free TRDA Stock Alerts $15.74 -0.06 (-0.38%) (As of 06/7/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 6 at 6:32 AM | americanbankingnews.comEntrada Therapeutics (NASDAQ:TRDA) Shares Gap Down to $15.70June 3, 2024 | globenewswire.comEntrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare ConferenceMay 28, 2024 | marketbeat.comEntrada Therapeutics (NASDAQ:TRDA) Trading 7% Higher Entrada Therapeutics (NASDAQ:TRDA) Trading 7% HigherMay 21, 2024 | insidertrades.comNatarajan Sethuraman Sells 1,000 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) StockMay 20, 2024 | marketbeat.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Insider Natarajan Sethuraman Sells 1,000 SharesEntrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) insider Natarajan Sethuraman sold 1,000 shares of Entrada Therapeutics stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $15.00, for a total transaction of $15,000.00. Following the completion of the sale, the insider now owns 208,032 shares in the company, valued at $3,120,480. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.May 17, 2024 | finance.yahoo.comDirector Peter Kim Acquires 25,000 Shares of Entrada Therapeutics Inc (TRDA)May 16, 2024 | globenewswire.comEntrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQMay 11, 2024 | insidertrades.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Director Acquires $31,955.04 in StockMay 10, 2024 | marketbeat.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Director Peter S. Kim Purchases 2,276 SharesEntrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) Director Peter S. Kim acquired 2,276 shares of the business's stock in a transaction dated Wednesday, May 8th. The shares were acquired at an average cost of $14.04 per share, with a total value of $31,955.04. Following the acquisition, the director now directly owns 65,212 shares of the company's stock, valued at approximately $915,576.48. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.May 8, 2024 | markets.businessinsider.comEntrada Therapeutics is about to announce earnings — here's what Wall Street expectsMay 8, 2024 | finance.yahoo.comEntrada Therapeutics First Quarter 2024 Earnings: Beats ExpectationsMay 7, 2024 | investorplace.comTRDA Stock Earnings: Entrada Therapeutics Beats EPS, Beats Revenue for Q1 2024May 7, 2024 | globenewswire.comEntrada Therapeutics Reports First Quarter 2024 Financial ResultsApril 14, 2024 | nasdaq.comFriday 4/12 Insider Buying Report: ATOS, TRDAApril 12, 2024 | insidermonkey.comInsiders are Piling into These 5 Healthcare Stocks in 2024April 11, 2024 | msn.comInsiders Buying America's Car-Mart And 2 Other StocksApril 11, 2024 | insidertrades.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Director Peter S. Kim Purchases 2,600 SharesApril 10, 2024 | marketbeat.comPeter S. Kim Buys 2,600 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) StockEntrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) Director Peter S. Kim acquired 2,600 shares of Entrada Therapeutics stock in a transaction that occurred on Monday, April 8th. The shares were bought at an average price of $13.57 per share, for a total transaction of $35,282.00. Following the transaction, the director now owns 62,936 shares of the company's stock, valued at approximately $854,041.52. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.April 2, 2024 | insidertrades.comPeter S. Kim Acquires 1,512 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) StockApril 1, 2024 | marketbeat.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Director Buys $20,790.00 in StockEntrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) Director Peter S. Kim bought 1,512 shares of Entrada Therapeutics stock in a transaction on Thursday, March 28th. The stock was acquired at an average cost of $13.75 per share, for a total transaction of $20,790.00. Following the acquisition, the director now owns 60,336 shares in the company, valued at approximately $829,620. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website.March 27, 2024 | finance.yahoo.comDirector Peter Kim Acquires 9,048 Shares of Entrada Therapeutics Inc (TRDA)March 27, 2024 | insidertrades.comPeter S. Kim Acquires 3,180 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) StockMarch 26, 2024 | marketbeat.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Director Buys $42,484.80 in StockEntrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) Director Peter S. Kim bought 3,180 shares of Entrada Therapeutics stock in a transaction dated Monday, March 25th. The stock was acquired at an average cost of $13.36 per share, with a total value of $42,484.80. Following the completion of the acquisition, the director now owns 56,074 shares of the company's stock, valued at $749,148.64. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.March 22, 2024 | insidertrades.comInsider Buying: Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Purchases 900 Shares of StockMarch 21, 2024 | marketbeat.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Director Peter S. Kim Purchases 900 SharesEntrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) Director Peter S. Kim bought 900 shares of the firm's stock in a transaction dated Tuesday, March 19th. The shares were acquired at an average cost of $12.66 per share, with a total value of $11,394.00. Following the completion of the transaction, the director now owns 47,944 shares of the company's stock, valued at $606,971.04. The purchase was disclosed in a legal filing with the SEC, which is available at this link.March 20, 2024 | marketbeat.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) to Post Q1 2024 Earnings of ($0.40) Per Share, HC Wainwright ForecastsEntrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Investment analysts at HC Wainwright issued their Q1 2024 earnings per share (EPS) estimates for Entrada Therapeutics in a note issued to investors on Monday, March 18th. HC Wainwright analyst R. Selvaraju forecasts that the company will eaMarch 19, 2024 | finance.yahoo.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Analysts Just Slashed This Year's EstimatesMarch 18, 2024 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Entrada Therapeutics (NASDAQ:TRDA)HC Wainwright restated a "buy" rating and set a $20.00 price target on shares of Entrada Therapeutics in a report on Monday.March 18, 2024 | markets.businessinsider.comEntrada Therapeutics: Buy Rating on Strong Financials and Promising Clinical PipelineMarch 18, 2024 | marketbeat.comEquities Analysts Offer Predictions for Entrada Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:TRDA)Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Investment analysts at William Blair lowered their Q1 2024 earnings per share estimates for Entrada Therapeutics in a research report issued to clients and investors on Wednesday, March 13th. William Blair analyst M. Minter now forecasts thMarch 13, 2024 | markets.businessinsider.comTD Cowen Reaffirms Their Buy Rating on Entrada Therapeutics Inc (TRDA)March 13, 2024 | finanznachrichten.deEntrada Therapeutics, Inc.: Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 13, 2024 | benzinga.comRecap: Entrada Therapeutics Q4 EarningsMarch 13, 2024 | globenewswire.comEntrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 23, 2024 | benzinga.comEntrada Therapeutics Stock (NASDAQ:TRDA) Insider TradesJanuary 29, 2024 | finance.yahoo.com‘Time to Pull the Trigger,’ Says Oppenheimer About These 3 StocksJanuary 18, 2024 | marketbeat.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) CEO Sells $15,990.00 in StockEntrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) CEO Dipal Doshi sold 1,000 shares of the business's stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $15.99, for a total value of $15,990.00. Following the transaction, the chief executive officer now owns 244,279 shares in the company, valued at approximately $3,906,021.21. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.January 8, 2024 | finance.yahoo.comAmicus (FOLD) Issues Preliminary Revenue Results for FY23January 6, 2024 | msn.comOppenheimer Initiates Coverage of Entrada Therapeutics (TRDA) with Outperform RecommendationJanuary 5, 2024 | marketbeat.comEntrada Therapeutics (NASDAQ:TRDA) Now Covered by OppenheimerOppenheimer started coverage on Entrada Therapeutics in a research note on Friday. They issued an "outperform" rating and a $22.00 price target on the stock.January 3, 2024 | finance.yahoo.comBEAM Stock Rallies More Than 25% in 3 Months: What Next?January 3, 2024 | finance.yahoo.comEntrada Therapeutics Promotes Nathan J. Dowden to PresidentDecember 28, 2023 | finance.yahoo.comEntrada Therapeutics Inc CFO Kory Wentworth Sells 12,500 SharesDecember 26, 2023 | marketbeat.comKory James Wentworth Sells 10,206 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) StockEntrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) CFO Kory James Wentworth sold 10,206 shares of the company's stock in a transaction on Friday, December 22nd. The shares were sold at an average price of $15.69, for a total transaction of $160,132.14. Following the completion of the sale, the chief financial officer now directly owns 49,571 shares of the company's stock, valued at approximately $777,768.99. The sale was disclosed in a filing with the SEC, which is accessible through this link.December 22, 2023 | marketbeat.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) CEO Dipal Doshi Sells 1,000 SharesEntrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) CEO Dipal Doshi sold 1,000 shares of the stock in a transaction dated Wednesday, December 20th. The shares were sold at an average price of $15.00, for a total value of $15,000.00. Following the sale, the chief executive officer now owns 245,279 shares of the company's stock, valued at $3,679,185. The sale was disclosed in a filing with the SEC, which is available through the SEC website.December 20, 2023 | finance.yahoo.comAnavex (AVXL) Rises as CHMP Deems Blarcamesine Eligible for MAADecember 20, 2023 | finance.yahoo.comRoche's (RHHBY) sBLA for Xolair Gets FDA Priority Review TagDecember 11, 2023 | benzinga.comEntrada Therapeutics Stock (NASDAQ:TRDA) Dividends: History, Yield and DatesDecember 11, 2023 | finance.yahoo.comPfizer's (PFE) Multiple Myeloma Drug Elrexfio Gets Nod in EUNovember 29, 2023 | benzinga.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Entrada Therapeutics, Inc. - TRDA Get Entrada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRDA and its competitors with MarketBeat's FREE daily newsletter. Email Address Time is Running Out - June 25th Deadline Approaching! (Ad)If you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you must get in now. Don’t delay. See all the details you need here. TRDA Media Mentions By Week TRDA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TRDA News Sentiment▼0.530.72▲Average Medical News Sentiment TRDA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TRDA Articles This Week▼21▲TRDA Articles Average Week Get Entrada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRDA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Amphastar Pharmaceuticals News Amneal Pharmaceuticals News Rocket Pharmaceuticals News Arvinas News Zai Lab News Catalyst Pharmaceuticals News Galapagos News Keros Therapeutics News Evotec News Protagonist Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TRDA) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersWe’ve Made 1,000% … THREE Different Times in the Last Year (Here’s How)Bitcoin can and probably will hit the $1 MILLION level this decade. That’s more than 1,000% upside from the...Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | Sponsored